Internationally 3% of the donor hearts are distributed to re-transplant patients. In Eurotransplant, only patients with a primary graft dysfunction (PGD) within 1 week after heart transplantation (HTX) are indicated for high urgency listing. The aim of this study is to provide evidence for the discussion on whether these patients should still be allocated with priority. All consecutive HTX performed in the period 1981-2015 were included. Multivariate Cox' model was built including: donor and recipient age and gender, ischaemia time, recipient diagnose, urgency status and era. The study population included 18 490 HTX, of these 463 (2.6%) were repeat transplants. The major indications for re-HTX were cardiac allograft vasculopathy (CAV) (50%), PGD (26%) and acute rejection (21%). In a multivariate model, compared with first HTX hazards ratio and 95% confidence interval for repeat HTX were 2.27 (1.83-2.82) for PGD, 2.24 (1.76-2.85) for acute rejection and 1.22 (1.00-1.48) for CAV (P < 0.0001). Outcome after cardiac re-HTX strongly depends on the indication for re-HTX with acceptable outcomes for CAV. In contrast, just 47.5% of all hearts transplanted in patients who were re-transplanted for PGD still functioned at 1-month post-transplant. Alternative options like VA-ECMO should be first offered before opting for acute re-transplantation.
Introduction
Attributable to surgical and medical advances, heart transplantation has become the preferred treatment option in selected patients with end-stage heart failure. Over the last three decades graft survival rates have significantly improved, but many patients who underwent heart transplantation will eventually have complications resulting in allograft failure [1, 2] .
Three percent of the available donor hearts are currently distributed to re-transplant patients [1] . In Eurotransplant (ET) the indications for high urgent listing of patients needing a cardiac re-transplantation have sharpened over the years (Table 1) , but those in need of a re-transplantation have, in contrast with the situation in the US, always received priority in organ allocation [3] .
As an integral part of the development of a new allocation scheme based on benefit instead of urgency, special recipient groups who cannot be judged by a score were defined; one of these groups consists of re-transplant candidates. The working group on the Cardiac Allocation Score convened in Leiden, the Netherlands on October 6, 2015 to discuss outcomes following re-transplantation [4] . Until the cardiac allocation score (CAS) system will be implemented, the urgency tier system will still determine the allocation policy. In its current form, patients suffering a primary graft dysfunction within 1 week after heart transplantation are indicated for high urgency (HU) listing.
There are three major ethical issues affecting allocation policy for repeat transplantation [5] . These three ethical considerations are the following: (i) the obligation a transplant team has to continue to offer the best possible care to a patient they previously transplanted, (ii) the fairness of assigning a second allograft while others die awaiting their first, and (iii) the difference in utility between primary and re-transplantation. Arguments to deny a heart re-transplant are usually based on this latter point, namely futility of the intervention, where medically futility is interpreted as an unacceptable likelihood of achieving life prolongation or a therapeutic benefit [6] .
In Eurotransplant one of five patients listed for a first heart transplantation dies on the waiting list within 3 years [7] . International data show that re-transplantation yields worse results compared with primary transplants, where the indication for the repeat transplant strongly determines the prognosis [8] [9] [10] .
The aim of this study is to examine the outcome after cardiac re-transplantation in the Eurotransplant cohort of 35 years in order to provide evidence for the discussion, whether patients suffering from primary graft dysfunction (PGD) within 1 week after heart transplantation should still be allocated heart allografts with high priority.
Materials and methods

Study design
Retrospective study including all consecutive heart transplantations performed in the Eurotransplant area.
Study population
All consecutive heart transplantations performed between January 1981 and December 2015 were included.
Statistical analysis
Survival rates were examined with time-to-event analysis in which the event was defined as graft failure, with censoring for death with functioning graft. For re-transplants, survival was computed from the date of the re-transplant.
Multivariate analysis included the following factors: donor and recipient age, donor and recipient gender, ischaemia time, recipient diagnose, urgency status and era of the transplant.
Continuous variables were analysed using WilcoxonMann-Whitney test, while Chi-square statistics were used to compare categorical variables. Survival analyses were performed by Kaplan-Meier method. Survival rates were compared using the log-rank test. All analyses were performed using SAS STATISTICAL program version 9.1 (SAS Institute, Cary, NC, USA). A P-value below 0.05 was considered statistically significant.
Results
Demographics
The study population included 18 490 heart transplants, of these 463 (2.6%) were repeat transplants with 447 second transplants, 15 third transplants and one patient received four heart transplants. The major indications for cardiac re-transplantation were cardiac allograft vasculopathy (50%), primary graft dysfunction (26%) and acute rejection (21%). Median time between the first and the re-transplants was 2 years and 10 months and ranged between 0 days and 27 years and 11 months. Donor, recipient and transplant characteristics are shown in Table 2 . Re-transplant rates over time have been stable around 2.5% (Fig. 1) , but indications for re-transplantation have shifted in this 35 year period (Fig. 2) . In the early years a majority of patients were re-transplanted following acute rejection and PGD, while in the latter decade the major indication for heart re-transplantation was cardiac allograft vasculopathy. (Fig. 3) .
Survival rates -Univariate analysis
Outcome after cardiac re-transplantation is compared with other diagnoses significantly worse (P < 0.0001) (Fig. 4) Figure 5 shows the graft survival by indication for retransplants and the outcome of first transplants. Compared with first transplant, patient re-transplanted after cardiac allograft vasculopathy (CAV) fared equally well with 1-month, 1-and 5-year rates of 89.5%, 79.3% and 67.8% for patient re-grafted after CAV and 87.9%, 78.0%, 68.3% for first HTX (P = 0.54). The graft survival for patients re-transplanted after PGD or rejection fared worse compared with first transplants with 1-month, 1-and 5-year rates of 47.5%, 39.7% and 35.1% for PGD and 70.9%, 51.9% and 40.6% for rejection (P < 0.0001).
The interval between transplants is significantly associated with graft survival (P < 0.0001) (Fig. 6 ). Early or acute re-transplants (<31 days) yielded 1-month, 1-and 5-year graft survival rates of 49.6%, 40.9% and 34.8%. If the interval was between 31 and 364 days the 1-month, 1-and 5-year graft survival rates were at 69.8%, 46.7% and 38.7%, and if the interval was 365 days or longer the 1-month, 1-and 5-year graft survival rates were: 88.3%, 76.8% and 64.7%.
Factors associated with overall graft survivalmultivariate analysis Donor and recipient age, recipient gender, cold ischaemia time, era of transplant and the indication for re-transplantation were found to be significantly associated with graft outcome (Table 3 ). The multivariate model showed that all three major indications 
Discussion
In Eurotransplant 2-3% of the available hearts are currently distributed to re-transplant patients where every year between 10 and 15 patients receive a second heart transplant.
Our data show that cardiac re-transplantation outcome has improved over the decades, but is still inferior to primary transplantation. Outcome after cardiac re-transplantation depends on the indication for retransplantation, and a shift in indication favouring the patients re-transplanted for cardiac allograft vasculopathy in the most recent years, is partly accountable for this improvement. In this 35 years Eurotransplant cohort, when compared with outcome after primary transplantation, graft survival for patients re-transplanted following primary graft dysfunction and rejection was significant worse with hazards ratios of 2.27 and 2.24 respectively, while the risk of graft loss for patients re-transplanted for cardiac allograft vasculopathy was 1.22.
Allocation rules are conceived and decided upon by clinicians -collaborating in the international organ advisory committee -but whose first job is to care for transplant candidates and recipients. As a consequence, since the early days acute re-transplantation has always been a standard indication for listing on the high urgency waiting list as this rule facilitates and supports the transplant teams that consider their patient eligible for acute re-transplantation [7] . However, with growing organ shortage, the role of the policy makers has changed towards being also the guardian of a shared scarce commodity where the fairness of assigning a second graft while other die awaiting their first, is a substantial ethical issue.
The graft survival rates for patients re-transplanted in Eurotransplanted after PGD at 1-month, 1-and 5-years were 47.5%, 39.7% and 35.1%, respectively. Given these jeopardized results, the Eurotransplant Thoracic Advisory Committee is currently discussing whether the allocation priority currently assigned to patients with PGD can be sustained. Until recently the only therapeutic option for PGD was a re-HTX. During the latest consensus conference on PGD after cardiac transplantation and confirmed by single centre experiences temporary ventricular assist devices and veno-arterial extracorporeal membrane oxygenation (VA-ECMO) can now be seen as established effective treatment options for severe PGD whose intervention can preclude emergency salvage re-transplantation [11, 12] . In the majority of cases (75-87%), donor hearts recovered and patients could be weaned from ECMO support with acceptable survival (55-70%) [13] . In the absence of randomized clinical trials, extracorporeal life support (ECLS) as bridge to recovery for severe PGD after heart transplant continues to be the first line of support with some recent evidence of improved outcomes as compared with short-term VAD use [14] . Based on the acceptable success rate of ECMO bridge to recovery and the better survival rates compared with those after acute re-transplantation we would consider a patient eligible for re-transplantation because of PGD only if he cannot be weaned from mechanical support, if he has good end-organ function (besides donor heart, kidney, liver, lung) and if he has a normal neurological condition.
Center volume and patient survival are consistently shown to be positively related in the ISHLT database [1] . As a result of its international composition in Eurotransplant this association is not so obvious as a large program in one country might be considered small in another country [15] . However the centre's expertise is instrumental in dealing with complicated cases and protocols for PGD treatment should be available and regularly be audited.
Acute rejection accounted for 21% of all cardiac retransplants in our total study cohort. Compared with first transplants, patient re-transplanted after rejection fared worse with 1-month, 1-and 5-year rates of 70.9%, 51.9% and 40.6%, respectively. However, during the last decade acute rejection as indication for re-transplantation has become an infrequent event. This is related to the fact that refractory acute rejection is rarely seen because of improvements with diagnosis allowing identification of high risk patients, early detection of events and because of improved treatment options like extracorporeal pheresis, the availability of new antibodies and better maintenance immunosuppression [16] . Monitoring immunosuppressive drug intake compliance should be rigidly undertaken; many of the patients with refractory severe rejection had adherence problems with medication and are therefore ineligible for re-transplantation [17] .
Current graft surveillance protocols for acute rejection entail invasive endo-myocardial biopsy, further research should focus on refining molecular analysis as a diagnostic tool [18] . This will be achieved by refining reference sets through accurate phenotyping of biopsy samples. Non-invasive biomarkers can then be refined according to the true pathological picture by using molecular analysis as a benchmark rather than subjective histology readings [19, 20] .
Our data show that outcome for patients re-transplanted after suffering CAV is excellent with 1-month, 1-and 5-year rates of 89.5%, 79.3% and 67.8%, respectively. However, with the availability of good long-term viable alternatives based on pharmacological management and percutaneous coronary intervention strategies, re-transplantation should be restricted to selected patients with CAV [21, 22] . Again, prevention is key and surveillance strategies by invasive angiography and intravascular ultrasound should be set up and executed [23] .
The limitations of this study are inherent to using registry data obtained from different transplant centres on a voluntary basis and where standardization of the definition of clinical events is difficult. Sabatino et al. [24] have recently shown that it is crucial not only to determine the aetiology of the graft dysfunction but most importantly it is to know the severity of the PGD as this will determine the clinical management strategy and the patient outcome. However, as the standard definitions and the grading system for PGD in heart transplantation only appeared in 2014, our data contain events using different definitions for PGD [11] .
In conclusion, our data show that cardiac re-transplantation outcome has improved over the decades, but is still inferior to primary transplantation. Outcome after cardiac re-transplantation depends on the indication and hence on the time span between the first and the re-transplantation. Only 47.5% of all hearts transplanted in patients who were re-transplanted for primary graft dysfunction still functioned at 1-month post-transplant. Alternative therapeutic options like VA-ECMO should be first offered before opting for an acute re-transplantation, since a sequential mode of treatment lowers the individual risk of the transplant patient.
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